Fibrates and cholestasis

Altered expression and function of canalicular transporters during early development of cholestatic liver injury in Abcb4-deficient mice

(2014) Shi-Ying Cai et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis

(2014) Marina G Silveira et al.   EXPERT OPINION ON PHARMACOTHERAPY

Fenofibrate-associated nephrotoxicity: A review of current evidence

(2013) R. L. Attridge et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Fenofibrate and the kidney: an overview

(2013) Michael S. Kostapanos et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion

(2013) Nisanne S. Ghonem et al.   HEPATOLOGY

Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid

(2013) Sabela Lens et al.   LIVER INTERNATIONAL

Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come

(2012) Nisanne S. Ghonem et al.   HEPATOLOGY

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

(2012) Akira Honda et al.   HEPATOLOGY

Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy

(2012) Xiao Feng HAN et al.   Journal of Digestive Diseases

Metabolomics reveals an essential role for peroxisome proliferator-activated receptor α in bile acid homeostasis

(2012) Fei Li et al.   JOURNAL OF LIPID RESEARCH

Profile of Serum Bile Acids in Noncholestatic Volunteers: Gender-Related Differences in Response to Fenofibrate

(2011) J Trottier et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment: The FIELD Study

(2011) R.-D. Ting et al.   DIABETES CARE

Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signali

(2011) Jin Chai et al.   HEPATOLOGY

Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity

(2011) Rebecca L. Attridge et al.   Journal of Clinical Lipidology

28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC

(2011) K.V. Kowdley et al.   JOURNAL OF HEPATOLOGY

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

(2010) C. Levy et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches

(2010) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

The Spectrum of Liver Diseases Related toABCB4Gene Mutations: Pathophysiology and Clinical Aspects

(2010) Anne Davit-Spraul et al.   SEMINARS IN LIVER DISEASE

The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study

(2008) Shinji Iwasaki et al.   HEPATOLOGY RESEARCH

PPARα: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators

(2007) Frank J. Gonzalez et al.   TOXICOLOGY